Launch metrics of Madrigal's MASH drug Rezdiffra track 'exceptionally well,' CEO says
With sales of $103 million in the fourth quarter and $180 million in its first nine months on the market, Madrigal Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis (MASH) treatment Rezdiffra has all the earmarks of a soon-to-be blockbuster.
With sales of $103 million in the fourth quarter and $180 million in its first nine months on the market, Madrigal Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis (MASH) treatment Rezdiffra has all the earmarks of a soon-to-be blockbuster.
